Amgen's (AMGN) Repatha Trail Met Primary Endpoint in Reducing Risk of Cardiovascular Events
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
